Name

Incidence et prévalence de la degenerescence maculaire exsudative en France de 2008 à 2018 - l'étude LANDSCAPE

This study aimed to estimate the incidence and prevalence of neovascular age related macular degeneration (nAMD) in the French population between 2008 and 2018.

Design: This was a retrospective longitudinal population study using healthcare consumption data from the French National Health Information database (Système National des Données de Santé [SNDS]), which covers about 99% of the French population.

Participants: We identified individuals treated for nAMD from the French population aged 50 years and older. Identification criteria were nAMD diagnosis or reimbursement of nAMD treatments (anti-VEGF intravitreal injection, or dynamic phototherapy with verteporfin). Exclusion criteria were high myopia, diagnosis of other retinal diseases, and other treatments for macular diseases (dexamethasone implant, laser, etc.).

Methods and outcome measures: We calculated incidence and prevalence, based on the age matched general population in France. Adjustment on age and sex was also performed for incidence.

Between 2008 and 2018, we identified 342,961 nAMD patients (65.2% female). Mean (SD) age at nAMD diagnosis or first treatment increased from 78.8 (8.1) years in 2008 to 81.2 (7.9) years in 2018. In 2018, annual incidence was 0.149% and prevalence was 1.062% for the French population aged ≥50 years. Incidence was stable over the 10-year period. Annual incidence increased with age (0.223%, 0.380% and 0.603% in those aged ≥60, ≥70 and ≥80 years, respectively), with similar trends for prevalence. No major differences observed among the 14 regions of France for incidence nor prevalence. nAMD incidence in 2018 was not impacted by the availability of primary or ophthalmology care in patients’ localities.

French National Health Information database can provide with interesting data to assess evolution of nAMD prevalence and incidence on a 10-year period. This can help plan resource allocation to ensure adequate patient care in the coming years with increase rate of aging population.

LANDSCAPE provides exhaustive nationwide data on incidence and prevalence of nAMD in France over a 10-year period.